In the Keynote 024 study, pembrolizumab effectively prolonged survival of NSCLC patients expressing PD-L1 in at least 50% of tumor cells compared to platinum-based chemotherapy in first-line setting [41-42]. Here, CD274 is linked to non-small cell lung carcinoma.